Table 5.

Acute adverse events (CTCAE ver4.0)

	Grade
	0	1	2	3	4	5	Grade 0-2	Grade 3-5	p value
(1) Hematotoxicity
Anemia									p=0.68
CF-RT group	2	23	43	15	0	0	68	15 (18.1%)
DCF-RT group	1	9	23	5	0	0	33	5 (13.2%)
Leukopenia									p=0.022
CF-RT group	2	8	27	35	9	0	37	46 (55.4%)
DCF-RT group	3	0	5	22	8	0	8	30 (78.9%)
Neutropenia									p=0.054
CF-RT group	3	24	17	32	7	0	44	39 (47.0%)
DCF-RT group	3	2	8	17	8	0	13	25 (65.8%)
Thrombopenia									p=0.80
CF-RT group	17	48	14	4	0	0	79	4 (4.8%)
DCF-RT group	8	24	3	2	1	0	35	3 (7.9%)
AST increasing									p=0.69
CF-RT group	60	20	3	0	0	0	83	0 (0%)
DCF-RT group	30	6	1	1	0	0	37	1 (2.6%)
ALT increasing									p=0.94
CF-RT group	49	25	6	3	0	0	80	3 (3.6%)
DCF-RT group	27	8	1	2	0	0	36	2 (5.3%)
Bilirubin increasing									p=1.0
CF-RT group	76	5	2	0	0	0	83	0 (0%)
DCF-RT group	32	5	1	0	0	0	38	0 (0%)
Creatinin increasing									p=1.0
CF-RT group	76	7	0	0	0	0	83	0 (0%)
DCF-RT group	28	10	0	0	0	0	38	0 (0%)
(2) Non-hematotoxicity
Radiation induced dermatitis									p=0.94
CF-RT group	22	35	25	1	0	0	82	1 (1.2%)
DCF-RT group	24	12	2	0	0	0	36	2 (5.3%)
Radiation esophagitis									p=0.58
CF-RT group	12	34	26	11	0	0	72	11 (13.3%)
DCF-RT group	17	9	9	3	0	0	35	3 (7.9%)

CTCAE; Common Terminology Criteria for Adverse Events, CF; cisplatin and 5-fluorouracil, DCF; docetaxel, cisplatin and 5-fluorouracil, AST; Aspartate transaminase, ALT; Alanine transaminase